August 26, 2021
Updated outcomes from the ongoing phase 1/2 GO40554 trial show that mosunetuzumab monotherapy demonstrated promising efficacy and a tolerable safety for elderly/unfit patients with previously untreated first-line diffuse large B-cell lymphoma.
August 19, 2021
An expert highlights the progress made with non–CAR T-based approaches in the non-Hodgkin lymphoma treatment paradigm, opportunities for sequencing available options, and ongoing efforts that are picking up momentum.
July 15, 2021
The consumer products giant voluntarily recalled 4 NEUTROGENA® and 1 AVEENO® spray sunscreen products July 14 after internal testing found low levels of benzene, a carcinogen, in some product samples.
June 06, 2021
A study from the 2021 ASCO Annual Meeting examined the effect that oral anticancer agent initiation may have on adherence rates in patients with multiple myeloma and chronic conditions.
A study from the 2021 ASCO Annual Meeting assessed the prevalence of oncology drug shortages and how they hinder care for patients with cancer.
June 05, 2021
A poster presentation at the 2021 ASCO Annual Meeting discussed survival trends among patients with chronic lymphocytic leukemia.
A community oncology practice implemented a team-based approach to utilizing biosimilars.
June 04, 2021
Results of the phase 3 OlympiA study evaluating olaparib as adjuvant therapy in high-risk early-stage breast cancer therapy were presented at the 2021 ASCO Annual Meeting.
A study highlighted at the 2021 ASCO Annual Meeting explored whether patients who received an influenza vaccine were at increased risk for immune-related adverse events from single-agent immune checkpoint inhibitors.
Results of the phase 3 RATIONALE 203 study were presented at the 2021 ASCO Annual Meeting.
